Ovid Therapeutics (OVID) Q4 2024 Annual Earnings
OVID·Reported March 11, 2025·Before market open
Ovid Therapeutics reported Q4 2024 revenue of $76.0K, missed analyst consensus of $100.0K by $24.0K. Diluted EPS came in at $-0.13, beat the $-0.16 consensus by $0.03.
Revenue
$76.0Kmissed by $24.0K
Consensus: $100.0KDiluted EPS
$-0.13beat by $0.03
Consensus: $-0.16
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Ovid Therapeutics's Q4 2024 earnings report.
Ovid Therapeutics (OVID) reported Q4 2024 earnings on March 11, 2025 before market open.
Ovid Therapeutics reported revenue of $76.0K and diluted EPS of $-0.13 for Q4 2024.
Revenue missed the consensus estimate of $100.0K by $24.0K. EPS beat the consensus estimate of $-0.16 by $0.03.
You can read the 10-K periodic report (0001628280-25-011844) directly on SEC EDGAR. The filing index links above go to sec.gov.